Home> Products> blood sugar monitoring and therapy

{ "products": [ { "_id": "68d51d9a26579f4bc195771a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg ", "description": "GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control.\n\nIt is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes.\n\n \n\nMechanism of Action\nThe therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism:\n\n1. Glimepiride (1 mg) – Sulfonylurea\nStimulates insulin secretion by activating pancreatic beta cells.\n\nProvides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas.\n\nHelps reduce both fasting and postprandial glucose levels.\n\n2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor\nDelays the breakdown and absorption of carbohydrates in the intestine.\n\nMinimizes post-meal glucose spikes (PPBG).\n\nActs locally in the gut and has minimal systemic absorption, which reduces systemic side effects.\n\n3. Metformin Hydrochloride SR (500 mg) – Biguanide\nDecreases hepatic glucose production (gluconeogenesis).\n\nImproves peripheral insulin sensitivity, enhancing glucose uptake in muscles.\n\nDoes not cause hypoglycemia on its own.\n\nThe sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects.\n\n \n\nIndications\nGLIMITERIS MV1 0.2 is indicated for:\n\nAdults with Type 2 Diabetes Mellitus.\n\nPatients inadequately controlled with monotherapy or dual therapy.\n\nManagement of fasting and postprandial hyperglycemia.\n\nLong-term HbA1c reduction as part of a comprehensive diabetes care plan.\n\n \n\nKey Benefits\n✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels.\n✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges.\n✅ Reduced Pill Burden – Combines three medicines into a single tablet.\n✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect.\n✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain.\n✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort.\n\n \n\nDosage and Administration\nRecommended dose: One tablet once or twice daily with meals, or as directed by the physician.\n\nAdministration tips:\n\nTake with the first bite of a main meal to maximize Voglibose’s effect.\n\nSwallow whole with water; do not crush or chew the SR tablet.\n\nDose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function.\n\n \n\nContraindications\nGLIMITERIS MV1 0.2 is not suitable for patients with:\n\nType 1 diabetes or diabetic ketoacidosis.\n\nSevere renal impairment (eGFR <30 mL/min/1.73 m²).\n\nHepatic dysfunction.\n\nSevere gastrointestinal diseases.\n\nHistory of lactic acidosis.\n\nHypersensitivity to Glimepiride, Voglibose, or Metformin.\n\nPregnancy and lactation (unless strictly advised by a physician).\n\n \n\nWarnings and Precautions\nHypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals.\n\nLactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential.\n\nGI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary).\n\nVitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption.\n\nLiver and Kidney Function: Regular monitoring is recommended for safe long-term use.\n\n \n\nAdverse Effects\nCommon:\nGlimepiride: Mild hypoglycemia, dizziness, slight weight gain.\n\nVoglibose: Gas, abdominal discomfort, mild diarrhea.\n\nMetformin SR: Nausea, bloating, metallic taste, loose stools.\n\nRare but Serious:\nLactic acidosis (from Metformin).\n\nSevere hypoglycemia (especially if meals are skipped).\n\nAllergic reactions such as rash, itching, or swelling.\n\nElevated liver enzymes.\n\nSeek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur.\n\n \n\nDrug Interactions\nIncreased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas.\n\nReduced Metformin efficacy: With corticosteroids, estrogens, and diuretics.\n\nLactic acidosis risk: Higher with alcohol or iodinated contrast agents. ", "price": 263.0, "discountamount": 80.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2182, "imageuri": "https://productimages.withfloats.com/actual/68d51d9cdf1a4ca2c252370a.png", "tileimageuri": "https://productimages.withfloats.com/tile/68d51d9cdf1a4ca2c252370a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-25T10:46:50.098Z", "updatedon": "2025-10-02T11:20:20.402Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-ip1-mg-voglibose-ip-0-2-mg-metformin-hydrochloride-ip-500-mg-/2182", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS MV1 0.2", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6891f29bfb7044dfb2d43adf", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "MAGRAL 160", "description": "MAGRAL 160 is a pharmaceutical medication containing megestrol acetate 160 mg, a synthetic progestin known for its potent antineoplastic and appetite-stimulating properties. This drug is primarily prescribed to manage significant health challenges such as unexplained weight loss, anorexia, and cachexia, especially in patients suffering from chronic conditions like cancer or AIDS. Additionally, megestrol acetate functions as a hormone therapy agent employed in the treatment of certain hormone-sensitive malignancies. Its dual action both supports tumor management and improves patients' nutritional status by stimulating appetite and promoting weight gain, thereby enhancing overall quality of life. The drug is regarded as a crucial option in oncology and palliative care for managing complex conditions related to hormone-dependent cancers and severe wasting syndromes.\n\nWhat is MAGRAL 160?\nMAGRAL 160 is an oral medication formulated with megestrol acetate 160 mg, a synthetic progestin hormone derivative. It works primarily by modulating hormone receptors and altering hormone levels that influence the growth of hormone-responsive tumors such as breast and endometrial cancers. Apart from its antineoplastic action, it stimulates appetite by acting on the hypothalamic centers responsible for hunger, helping patients suffering from severe weight loss regain a healthy appetite and weight.\n\nUses of MAGRAL 160\n\nTo treat hormone-dependent cancers, specifically advanced breast cancer and endometrial cancer.\n\nTo stimulate appetite and promote weight gain in patients experiencing anorexia, cachexia, or unexplained severe weight loss related to chronic illnesses like cancer or AIDS.\n\nTo manage wasting syndromes that lead to malnutrition and significant weight loss.\n\nTo serve as an antineoplastic agent in hormone-sensitive malignancies.\n\nIn short, MAGRAL 160 is primarily used to treat anorexia and cachexia or serious unexplained weight loss and is also used as an antineoplastic agent to treat certain types of malignancy.\n\nSide Effects of MAGRAL 160\n\nWeight gain (often desirable but can be excessive)\n\nFluid retention and edema (swelling)\n\nNausea and vomiting\n\nDiarrhea or constipation\n\nVaginal bleeding or spotting in women\n\nFatigue, weakness, and insomnia\n\nHeadache and dizziness\n\nIncreased risk of blood clots (deep vein thrombosis or pulmonary embolism)\n\nHormonal imbalances, such as decreased sex hormone levels, which can lead to sexual dysfunction or bone density loss\n\nAllergic reactions including rash or itching\n\nPatients should report severe or unusual symptoms, especially signs of blood clots such as limb swelling, chest pain, or sudden shortness of breath, immediately to their healthcare provider.\n\nPrecautions before Using MAGRAL 160\n\nInform your doctor if you are pregnant, breastfeeding, or planning to conceive as MAGRAL 160 is contraindicated in pregnancy.\n\nDisclose any history of blood clots, cardiovascular diseases, liver or kidney impairment.\n\nPatients with diabetes should monitor blood sugar closely as megestrol acetate may cause hyperglycemia.\n\nAvoid sudden discontinuation without medical advice to prevent potential hormonal withdrawal effects.\n\nRegular monitoring is required, including hormone levels and blood tests, to assess efficacy and safety during treatment.\n\nUse cautiously in patients at risk for deep vein thrombosis or pulmonary embolism due to increased clotting risks.\n\nDrug Interactions: What Drugs Interact with MAGRAL 160?\n\nCYP3A4 enzyme inducers (e.g., rifampin, phenytoin) may reduce the effectiveness of megestrol acetate by increasing its metabolism.\n\nConcurrent use with blood thinners (anticoagulants) requires careful monitoring as MAGRAL 160 might influence clotting parameters.\n\nCombining with drugs that affect hormonal pathways, such as other hormonal therapies or corticosteroids, may alter treatment outcomes.\n\nInteractions with diabetes medications might necessitate dose adjustment due to potential effects on blood sugar control.\n\nCareful medical supervision is necessary when used with immunosuppressants or other chemotherapy agents to avoid additive side effects or altered drug levels.\n\nConclusion\nMAGRAL 160, containing megestrol acetate 160 mg, is a clinically validated medication widely used to manage complex conditions such as hormone-dependent cancers as well as severe weight loss due to anorexia and cachexia. Its unique ability to act both as an antineoplastic agent and an appetite stimulant makes it invaluable in improving patient outcomes, nutritional status, and overall quality of life. Patients prescribed MAGRAL 160 should adhere strictly to their healthcare provider’s instructions and report any adverse effects promptly. This medication should always be used under medical supervision to ensure optimal benefits and minimize risks.", "price": 810.0, "discountamount": 243.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2156, "imageuri": "https://productimages.withfloats.com/actual/6891f2a0115b51057b971998.png", "tileimageuri": "https://productimages.withfloats.com/tile/6891f2a0115b51057b971998.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-05T12:01:31.195Z", "updatedon": "2025-08-05T12:01:31.195Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/magral-160/2156", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "megestrol acetate 160 mg", "category": "Gynaecology", "tags": [ "megestrol acetate 160 mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6890aa548a215c65672372e1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "EMPATECH LINA 25/5", "description": "EMPATECH LINA 25/5 is a pharmaceutical tablet containing a combination of two active ingredients: Empagliflozin 25MG and Linagliptin 5MG. This medication is designed to help manage blood sugar levels in adults with type 2 diabetes mellitus. The combination works through complementary mechanisms to improve glycemic control more effectively than either drug alone. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that promotes the excretion of excess glucose through urine, while Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and suppresses glucagon release, particularly after meals. EMPATECH LINA 25/5 is generally prescribed alongside a balanced diet and regular exercise to optimize blood sugar management and reduce the risk of diabetes-related complications such as kidney damage, neuropathy, and cardiovascular issues.\n\nWhat is EMPATECH LINA 25/5?\n\nEMPATECH LINA 25/5 is a prescription medication combining Empagliflozin (25MG) and Linagliptin (5MG) tablets used to manage type 2 diabetes. It helps control elevated blood sugar levels by using dual actions — the removal of glucose via kidneys and improving pancreatic hormone responses. This combination aims to achieve better and sustained glycemic control, often necessary for patients who have inadequate blood sugar control with other treatments.\n\nUses of EMPATECH LINA 25/5\n\nTo improve blood sugar control in adults with type 2 diabetes, particularly when monotherapy is insufficient.\n\nOften used as a second-line therapy after metformin or when metformin is not tolerated.\n\nTo reduce HbA1c (hemoglobin A1c), an important measure of long-term glucose control.\n\nMay help reduce weight and blood pressure as empagliflozin aids in glucose excretion.\n\nSupports comprehensive diabetes management along with diet and exercise.\n\nPrevents or reduces the risk of diabetes-associated complications such as kidney disease, cardiovascular events, and nerve damage.\n\nSide Effects of EMPATECH LINA 25/5\n\nCommon side effects may include urinary tract infections and genital infections due to increased glucose in urine.\n\nIncreased urination and dehydration.\n\nDizziness or lightheadedness, especially when standing up quickly.\n\nHypoglycemia (low blood sugar), though rare with this combination.\n\nGastrointestinal symptoms such as nausea or diarrhea.\n\nPotential increased risk of ketoacidosis (a serious condition related to high blood acids) in rare cases.\n\nAllergic reactions, although uncommon, may occur and require prompt medical attention.\n\nPrecautions Before Using EMPATECH LINA 25/5\n\nInform your healthcare provider if you have kidney disease, liver problems, or a history of urinary tract infections.\n\nNot recommended for type 1 diabetes or diabetic ketoacidosis treatment.\n\nUse with caution if you are pregnant, planning to become pregnant, or breastfeeding.\n\nStay hydrated while on this medication to reduce the risk of dehydration and dizziness.\n\nInform your doctor about any history of pancreatitis or pancreas disorders.\n\nRegular monitoring of kidney function and blood sugar levels is advised during treatment.\n\nAvoid drinking excessive alcohol as it may increase side effects or risk of ketoacidosis.\n\nDrug Interactions: What Drugs Interact with EMPATECH LINA 25/5?\n\nOther antidiabetic medications, such as insulin or sulfonylureas, may increase the risk of hypoglycemia.\n\nDiuretics, blood pressure medications, and lithium may interact and increase side effects.\n\nDrugs that impair kidney function can affect empagliflozin’s efficacy and safety.\n\nCertain enzyme-inducing drugs may reduce linagliptin levels, lowering its effectiveness.\n\nConsult your healthcare provider for a full list of possible interactions and before starting any new medication, including over-the-counter drugs or supplements.\n\nConclusion\n\nEMPATECH LINA 25/5, containing Empagliflozin 25MG and Linagliptin 5MG, is an effective combination medication to treat high blood sugar levels caused by type 2 diabetes. Its dual-action approach targets different physiological mechanisms to improve blood glucose control, helping reduce the risks and complications associated with diabetes. While it is generally well-tolerated, awareness of possible side effects and drug interactions is important. Always use under medical supervision, alongside lifestyle modifications such as diet and exercise, for optimal diabetes management.", "price": 345.0, "discountamount": 104.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2154, "imageuri": "https://productimages.withfloats.com/actual/6890aa58dd0bc098c3220f4c.png", "tileimageuri": "https://productimages.withfloats.com/tile/6890aa58dd0bc098c3220f4c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-04T12:40:52.619Z", "updatedon": "2025-08-04T12:40:52.619Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empatech-lina-25-5/2154", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Empagliflozin and Linagliptin Tablets", "category": "DIABETIC RANGE", "tags": [ "Empagliflozin and Linagliptin Tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68822dd35b399ba6097ed11b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "SEIZMET G 0.5 FORTE", "description": "SEIZMET G0.5 FORTE is a powerful oral antidiabetic medication formulated with a combination of glimepiride and metformin hydrochloride. This dual-action therapy is specifically designed for patients with type 2 diabetes mellitus who are unable to control their blood sugar levels with diet and exercise alone. The combination works in synergy to manage blood glucose effectively, reduce insulin resistance, and improve overall glycemic control.\n\nGlimepiride and metformin hydrochloride tablets are a combination medication used to treat type 2 diabetes. They work by helping the pancreas release more insulin and by reducing the amount of sugar produced by the liver, while also making the body more sensitive to insulin.\n\nWhat is SEIZMET G0.5 FORTE?\nSEIZMET G0.5 FORTE contains two active ingredients:\n\nGlimepiride (0.5 mg): A sulfonylurea class drug that stimulates the beta cells of the pancreas to release insulin.\n\nMetformin Hydrochloride: A biguanide that works primarily by suppressing hepatic glucose production and increasing insulin sensitivity in muscles.\n\nTogether, this combination addresses both insulin deficiency and resistance—two key factors in type 2 diabetes.\n\nUses of SEIZMET G0.5 FORTE:\n\nEffective in managing type 2 diabetes mellitus\n\nHelps in reducing fasting and postprandial blood glucose levels\n\nUsed as monotherapy or in combination with other antidiabetic agents\n\nReduces the risk of diabetic complications such as nephropathy, retinopathy, and cardiovascular disease\n\nSide Effects of SEIZMET G0.5 FORTE:\nLike all medications, glimepiride and metformin hydrochloride tablets may cause side effects in some patients. Common side effects include:\n\nNausea or vomiting\n\nDiarrhea\n\nHypoglycemia (low blood sugar)\n\nHeadache\n\nDizziness\n\nMetallic taste in the mouth\n\nAbdominal discomfort\n\nIn rare cases, it may cause lactic acidosis, a serious condition related to metformin accumulation.\n\nPrecautions Before Using SEIZMET G0.5 FORTE:\n\nAlways take the medication exactly as prescribed by your doctor.\n\nInform your physician if you have a history of liver or kidney disorders, heart disease, or alcohol abuse.\n\nAvoid excessive alcohol consumption while on this medication as it increases the risk of lactic acidosis.\n\nNot recommended for patients with type 1 diabetes or diabetic ketoacidosis.\n\nRegularly monitor your blood sugar and kidney function.\n\nThis medicine should be used during pregnancy only if absolutely necessary and under medical supervision.\n\nDrug Interactions: What Drugs Interact with SEIZMET G0.5 FORTE?\nCertain medications can interact with glimepiride and metformin, affecting their efficacy or increasing the risk of side effects. These include:\n\nBeta-blockers (e.g., propranolol) – may mask hypoglycemia symptoms\n\nDiuretics – may impair blood sugar control\n\nACE inhibitors – may increase the blood glucose-lowering effect\n\nCorticosteroids – may reduce the effectiveness of the medication\n\nAntipsychotics (e.g., olanzapine)\n\nAlcohol – increases the risk of lactic acidosis\n\nCimetidine – may raise metformin levels in the body\n\nAlways inform your healthcare provider about all medications, supplements, or herbal products you are taking.\n\nConclusion:\nSEIZMET G0.5 FORTE is a trusted, effective choice for managing type 2 diabetes, offering the combined benefits of glimepiride and metformin hydrochloride tablets. With dual mechanisms—enhancing insulin secretion and improving insulin sensitivity—it delivers comprehensive glycemic control. When taken as directed and with regular monitoring, SEIZMET G0.5 FORTE can be a valuable part of a diabetic patient’s treatment regimen, contributing to a healthier, more balanced life.\n\nFor best results, pair this medication with a proper diet, regular physical activity, and periodic blood glucose testing. Always consult your healthcare provider for personalized advice.", "price": 125.0, "discountamount": 38.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2151, "imageuri": "https://productimages.withfloats.com/actual/68822dd8296c4d19d55e8535.png", "tileimageuri": "https://productimages.withfloats.com/tile/68822dd8296c4d19d55e8535.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-07-24T12:57:55.385Z", "updatedon": "2025-07-24T12:57:55.385Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/seizmet-g-0-5-forte/2151", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "glimepiride and metformin hydrochloride tablets", "category": "DIABETIC RANGE", "tags": [ "glimepiride and metformin hydrochloride tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67e151dde76674b1ca044d32", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin 25 mg and Sitagliptin 100 mg", "description": "GLIEMPAFLOZIN SITA 25/100 is an advanced anti-diabetic medication containing Empagliflozin 25 mg and Sitagliptin 100 mg, formulated to effectively control blood sugar levels in individuals with Type 2 Diabetes Mellitus. This powerful combination helps regulate glucose levels, improve insulin function, and reduce the risk of diabetes-related complications. It is designed for patients requiring dual therapy to achieve better glycemic control.\n\n \nKey Benefits:\n \nEffective Blood Sugar Control – Lowers HbA1c levels and maintains long-term glycemic stability.\nPromotes Weight Loss – Empagliflozin helps in reducing excess body weight by eliminating excess glucose.\nHeart & Kidney Protection – Reduces the risk of cardiovascular diseases and kidney complications.\nEnhanced Insulin Sensitivity – Improves insulin response and minimizes glucose spikes.\nConvenient Dual Therapy – Combines two powerful anti-diabetic agents in one tablet for better diabetes management.\n\n \nHow Does It Work?\n \n\nEmpagliflozin blocks the SGLT2 protein in the kidneys, preventing glucose reabsorption and promoting glucose excretion through urine. This helps lower blood sugar levels naturally while supporting heart and kidney health.\n\nSitagliptin works by inhibiting the DPP-4 enzyme, which increases the levels of incretin hormones that stimulate insulin release and reduce glucose production in the liver.\n\nTogether, they offer comprehensive diabetes control by lowering blood sugar through different mechanisms, making it a superior option for Type 2 Diabetes management.\n\n \nDirections for Use:\n \n\nTake GLIEMPAFLOZIN SITA 25/100 as prescribed by your doctor.\n\nSwallow the tablet whole with water, preferably once daily with or without food.\n\nMaintain a healthy diet and regular exercise for best results.\n\nDo not exceed the recommended dosage without consulting a healthcare professional.\n\n \nSide Effects:\n \n\nWhile generally well-tolerated, some users may experience:\n\nFrequent Urination (due to glucose excretion)\nDehydration & Dizziness\nMild Nausea or Stomach Discomfort\nHypoglycemia (Low Blood Sugar) – Especially if combined with insulin or sulfonylureas\nUrinary or Genital Infections (due to increased sugar excretion in urine)\n\nSeek medical attention if you experience severe allergic reactions, persistent dizziness, or signs of dehydration.", "price": 425.0, "discountamount": 128.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "sulfonylureas urinary", "generally welltolerated", "recommended dosage", "regular exercise", "healthy diet", "food maintain", "water preferably", "doctor swallow", "gliempaflozin sita 25100", "superior option", "mechanisms making", "incretin hormones", "dpp4 enzyme", "supporting heart", "sglt2 protein", "diabetes management", "cardiovascular diseases", "diabetesrelated complications", "empagliflozin 25mg", "reduce glucose production", "stimulate insulin release", "work empagliflozin blocks", "increased sugar excretion", "genital infections due", "lowering blood sugar", "promoting glucose excretion", "powerful antidiabetic agents", "sitagliptin 100mg formulated", "advanced antidiabetic medication" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2071, "imageuri": "https://productimages.withfloats.com/actual/67e151f4a5330495f6fabda3.png", "tileimageuri": "https://productimages.withfloats.com/tile/67e151f4a5330495f6fabda3.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-03-24T12:36:45.699Z", "updatedon": "2025-03-27T13:02:48.654Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-25-mg-and-sitagliptin-100-mg/2071", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN SITA 25/100", "category": "DIABETIC RANGE", "tags": [ "Empagliflozin and sitagliptin combination", "Empagliflozin 25 mg substitute", "Empagliflozin 25 mg brands in India", "Empagliflozin 25 mg Price in India", "Empagliflozin brands in India", "Empagliflozin 25 mg", "Empagliflozin" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67a35d815432f8f0afe662b4", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "empagliflozin 25mg+ metformin hydrochloride (extended release) 1000 mg", "description": "GLIEMPAFLOZIN MET ER is a combination medication used to manage type 2 diabetes mellitus (T2DM) by helping control blood sugar levels effectively. It contains two powerful anti-diabetic agents, Empagliflozin and Metformin Hydrochloride (Extended Release), which work together to enhance glucose regulation and reduce the risk of diabetes-related complications. This medication is recommended for patients who require additional glycemic control beyond lifestyle changes and monotherapy treatments.\n\n \nKey Benefits\n \n\n Effective Blood Sugar Control – Helps reduce and maintain optimal blood glucose levels in type 2 diabetic patients.\nWeight Management – Empagliflozin promotes caloric loss through urinary glucose excretion, potentially aiding in weight reduction.\nReduced Risk of Cardiovascular Diseases – Beneficial for heart health, lowering the risk of cardiac complications in diabetic patients.\nInsulin Sensitivity Improvement – Metformin enhances insulin function, reducing insulin resistance.\nLower Risk of Hypoglycemia – A balanced mechanism of action ensures stable blood glucose levels without sudden drops.\nKidney Protection – Empagliflozin may help protect against diabetic nephropathy by reducing kidney stress.\nExtended-Release Formula – Ensures long-lasting blood sugar control with a once-daily dosage for improved patient compliance.\n \nHow Does It Work?\n \n\nEmpagliflozin (SGLT2 Inhibitor) – Blocks the SGLT2 protein in the kidneys, preventing glucose reabsorption and promoting its excretion through urine, thereby reducing blood sugar levels.\nMetformin Hydrochloride (Biguanide) – Reduces glucose production in the liver, enhances insulin response, and delays glucose absorption in the digestive tract.\nTogether, they provide a dual action approach for better glycemic control while minimizing side effects like hypoglycemia.\n \nDirections for Use\n \n\nDosage: Take one tablet per day, preferably with food or as directed by your healthcare provider.\nSwallow whole with a glass of water; do not crush or chew.\n Maintain a healthy diet and follow a regular exercise routine for optimal results.\nRegular monitoring of blood sugar levels is advised.\nDo not stop taking this medication without consulting your doctor.\n\n \nSide Effects:\n \n\nSome individuals may experience mild to moderate side effects, including:\n\nFrequent urination (due to glucose excretion)\nDehydration (increased fluid loss)\nNausea, vomiting, or stomach upset\nDiarrhea or constipation\nMetallic taste in the mouth\nLow blood pressure (Hypotension)\nVitamin B12 deficiency (with long-term use of Metformin)\nUrinary tract infections (UTIs) or genital infections\n Seek medical attention if you experience severe allergic reactions, extreme dizziness, or difficulty breathing.", "price": 245.0, "discountamount": 74.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "combination medication", "hypoglycemia directions", "oncedaily dosage", "difficulty breathing", "experience mild", "stop taking", "healthy diet", "chew maintain", "day preferably", "glycemic control", "digestive tract", "sglt2 protein", "diabetic nephropathy", "balanced mechanism", "cardiac complications", "diabetesrelated complications", "constipation metallic taste", "stomach upset diarrhea", "frequent urination due", "moderate side effects", "doctor side effects", "blood sugar levels", "regular exercise routine", "healthcare provider swallow", "minimizing side effects", "dual action approach", "delays glucose absorption", "improved patient compliance", "heart health lowering", "cardiovascular diseases beneficial", "enhance glucose regulation" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2049, "imageuri": "https://productimages.withfloats.com/actual/67a35d9d1b599c6f20ba1fa7.png", "tileimageuri": "https://productimages.withfloats.com/tile/67a35d9d1b599c6f20ba1fa7.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-02-05T12:45:53.712Z", "updatedon": "2025-03-27T09:45:21.627Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-25mg-metformin-hydrochloride-extended-release-1000-mg/2049", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN MET ER ", "category": "DIABETIC RANGE", "tags": [ "empagliflozin/metformin 5 mg/1000 mg", "empagliflozin + metformin brand name in india", "empagliflozin + metformin combination brand name", "empagliflozin 12.5 mg+metformin 500 mg price", "Empagliflozin and metformin hydrochloride extended-release tablets", "Empagliflozin and metformin hydrochloride tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67a35c945c5e728a14d08ad8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin (25mg), Linagliptin (5mg)", "description": "GLIEMPAFLOZIN LINA 25mg/5mg is a combination medication designed for individuals managing type 2 diabetes mellitus. It contains Empagliflozin (25mg) and Linagliptin (5mg), two potent anti-diabetic agents that work together to control blood sugar levels effectively. This medication is typically prescribed to patients who require dual therapy to achieve optimal glycemic control when diet and exercise alone are insufficient.\n\n \nKey Benefits :\n \n\nEffective Blood Sugar Control: Regulates blood glucose levels efficiently in patients with type 2 diabetes.\n\nWeight Management: Empagliflozin promotes weight loss by removing excess glucose from the body.\n\nHeart and Kidney Benefits: Shown to provide cardiovascular and renal protection, reducing the risk of heart failure.\n\nLower Risk of Hypoglycemia: Minimal chances of low blood sugar episodes compared to other anti-diabetic medications.\n\nConvenient Dual Therapy: Combines two complementary mechanisms for enhanced glycemic control in a single tablet.\n\n \nHow Does It Work?\n \n\nEmpagliflozin (SGLT2 Inhibitor): This component blocks Sodium-Glucose Cotransporter-2 (SGLT2) in the kidneys, preventing glucose reabsorption and facilitating its elimination through urine. This leads to a significant reduction in blood sugar levels.\n\nLinagliptin (DPP-4 Inhibitor): It inhibits Dipeptidyl Peptidase-4 (DPP-4) enzyme, which increases incretin hormone levels. This enhances insulin secretion and suppresses glucagon production, leading to better post-meal glucose control.\n\n \nDirections for Use\n \n\nTake one tablet daily, preferably at the same time each day.\n\nSwallow the tablet whole with water, with or without food.\n\nFollow the dosage regimen prescribed by your healthcare provider.\n\nRegular monitoring of blood sugar levels is recommended.\n\n \nSide Effects\n \n\nAlthough GLIEMPAFLOZIN LINA 25mg/5mg is generally well-tolerated, some patients may experience:\n\nFrequent Urination: Due to glucose excretion through urine.\n\nDehydration or Thirst: Increased urination may lead to mild dehydration.\n\nUrinary Tract Infections (UTIs): A common side effect associated with SGLT2 inhibitors.\n\nNasal Congestion or Sore Throat: Occasionally observed with DPP-4 inhibitors.\n\nGastrointestinal Discomfort: Mild nausea or diarrhea in some cases.\n\nHypotension (Low Blood Pressure): Especially in patients with pre-existing conditions.\n\n ", "price": 345.0, "discountamount": 104.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "urine dehydration", "preexisting conditions", "generally welltolerated", "food follow", "day swallow", "significant reduction", "single tablet", "complementary mechanisms", "provide cardiovascular", "body heart", "linagliptin 5mg", "empagliflozin 25mg", "glucose excretion", "typically prescribed", "tablet daily preferably", "combination medication designed", "dosage regimen prescribed", "removing excess glucose", "common side effect", "thirst increased urination", "gliempaflozin lina 25mg5mg", "recommended side effects", "blood sugar levels", "enhances insulin secretion", "enhanced glycemic control", "hypoglycemia minimal chances", "renal protection reducing", "kidney benefits shown", "require dual therapy", "potent antidiabetic agents" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2048, "imageuri": "https://productimages.withfloats.com/actual/67a35cb9b07d7c125c0f536d.png", "tileimageuri": "https://productimages.withfloats.com/tile/67a35cb9b07d7c125c0f536d.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-02-05T12:41:56.39Z", "updatedon": "2025-03-17T11:04:56.55Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-25mg-linagliptin-5mg-/2048", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN LINA 25mg/ 5mg", "category": "DIABETIC RANGE", "tags": [ "empagliflozin-linagliptin 25-5 mg price", "Empagliflozin and Linagliptin brands in India", "empagliflozin-linagliptin 10-5 mg", "Fixed dose combination of Empagliflozin and Linagliptin Tablets Price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662aa04db100e1fdc2dcb68", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE 100 ", "description": "VILDIABATE 100 \nVildagliptin (100mg)\nVILDIABATE 100 is a medication designed to manage type 2 diabetes mellitus by targeting specific aspects of glucose regulation. It contains Vildagliptin, an oral antidiabetic agent that belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. Vildagliptin works by inhibiting the enzyme DPP-4, which is responsible for degrading incretin hormones like GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide).\n\nHere are key points about VILDIABATE 100:\n\nMechanism of Action: Vildagliptin acts by inhibiting DPP-4, thereby increasing the levels of GLP-1 and GIP. These hormones play crucial roles in glucose metabolism:\n\nGLP-1 stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner. It also inhibits glucagon secretion, reduces appetite, and slows gastric emptying.\nGIP enhances insulin release in response to meals, contributing to postprandial glucose control.\nBlood Sugar Control: By enhancing insulin secretion and reducing glucagon levels, VILDIABATE 100 helps lower blood sugar levels, especially after meals. This mechanism targets both fasting and postprandial hyperglycemia, contributing to overall glycemic control.\n\nDosage and Administration: VILDIABATE 100 is typically taken orally once daily, preferably with a meal to maximize its effects on postprandial glucose levels. The dosage may vary depending on individual needs and response to treatment. It's essential to follow your healthcare provider's instructions regarding dosage and timing.\n\nEfficacy and Safety: Clinical studies have demonstrated the efficacy of Vildagliptin in lowering HbA1c levels (a marker of long-term glucose control) and improving glycemic parameters. It is generally well-tolerated, with common side effects including headache, nasopharyngitis (inflammation of the nose and throat), and upper respiratory tract infections. Serious side effects are rare but may include pancreatitis or hypersensitivity reactions.\n\nCombination Therapy: VILDIABATE 100 may be prescribed as monotherapy or in combination with other antidiabetic medications such as metformin or sulfonylureas. Combining medications with different mechanisms of action can provide synergistic benefits in managing diabetes.\n\nMonitoring and Follow-Up: Regular monitoring of blood sugar levels, kidney function, and other relevant parameters is important during treatment with VILDIABATE 100. Your healthcare provider may adjust the dosage or add/modify other medications based on your response and individual needs.\n\nLifestyle Modifications: In addition to medication, lifestyle modifications such as a healthy diet, regular exercise, weight management, and avoiding tobacco and excessive alcohol intake are essential components of diabetes management.\n\nIn conclusion, VILDIABATE 100 containing Vildagliptin is an effective oral antidiabetic medication that helps regulate blood sugar levels in patients with type 2 diabetes. It acts by enhancing insulin secretion and reducing postprandial glucose levels, contributing to improved glycemic control. However, it should be used under medical supervision, and adherence to prescribed dosage and lifestyle recommendations is crucial for optimal diabetes management.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-100-133452\n\n\n\n\n\n", "price": 275.0, "discountamount": 82.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "nose", "GLP-1", "EMAIL", "class", "meals", "Order", "timing", "throat", "enzyme", "Safety", "Dosage", "marker", "tobacco", "fasting", "response", "addition", "appetite", "headache", "patients", "Efficacy", "metformin", "Follow-Up", "adherence", "treatment", "VILDIABATE", "conclusion", "key points", "information", "monotherapy", "healthy diet", "instructions", "sterisonline", "pancreatitis", "inflammation", "sterispharma", "HbA1c levels", "CALL/WHATSAPP", "sulfonylureas", "crucial roles", "Administration", "insulin release", "nasopharyngitis", "kidney function", "glucagon levels", "gastric emptying", "specific aspects", "Clinical studies", "individual needs", "regular exercise", "other medications", "Vildagliptin acts", "incretin hormones", "DPP-4) inhibitors", "weight management", "insulin secretion", "glucose metabolism", "glucose regulation", "glucagon secretion", "blood sugar levels", "Regular monitoring", "Combination Therapy", "glycemic parameters", "common side effects", "Blood Sugar Control", "medical supervision", "healthcare provider", "essential components", "synergistic benefits", "different mechanisms", "Serious side effects", "pancreatic beta cells", "dipeptidyl peptidase-4", "oral antidiabetic agent", "Lifestyle Modifications", "glucose-dependent manner", "excessive alcohol intake", "overall glycemic control", "type 2 diabetes mellitus", "lifestyle recommendations", "other relevant parameters", "long-term glucose control", "hypersensitivity reactions", "postprandial hyperglycemia", "optimal diabetes management", "postprandial glucose levels", "postprandial glucose control", "other antidiabetic medications", "upper respiratory tract infections", "effective oral antidiabetic medication", "glucose-dependent insulinotropic peptide" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1491, "imageuri": "https://productimages.withfloats.com/actual/6662aa0b364f23242470b3ca.png", "tileimageuri": "https://productimages.withfloats.com/tile/6662aa0b364f23242470b3ca.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T06:34:44.056Z", "updatedon": "2024-06-28T11:58:50.164Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//vildiabate-100-/1491", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE 100 ", "category": "DIABETIC RANGE", "tags": [ "VILDIABATE 100", "Vildagliptin (100mg)", "Vildagliptin 100 mg uses", "Vildagliptin 100 mg price", "Vildagliptin 100 mg SR brand Name", "Vildagliptin 100 mg brands in India", "", "Vildagliptin 100 mg generic medicine", "Vildagliptin 100 mg side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "665ef948161afa2274ff25b9", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGALZE MR 60 ", "description": "GLICLAGALZE MR 60 \nGliclazide SR 60 mg\nIntroduction\nGLICLAGALZE MR 60 is an oral medication tailored for the treatment of Type 2 diabetes, featuring a 60 mg dose of Gliclazide in a sustained release (SR) formulation. This medication is designed to offer consistent control of blood sugar levels throughout the day, minimizing fluctuations and improving overall diabetes management.\n\nMechanism of Action\n\nGliclazide SR (60 mg): Gliclazide is a member of the sulfonylurea class of diabetes medications. It operates by stimulating the pancreatic beta cells to produce more insulin, a key hormone that helps lower blood glucose. The SR formulation allows for a gradual release of Gliclazide, maintaining a steady level of the drug in the bloodstream, which helps to prevent the peaks and troughs in blood sugar levels that can be problematic in diabetes management.\nBenefits\nGLICLAGALZE MR 60 is particularly beneficial for patients who need a moderate increase in their insulin production but are concerned about the risks of hypoglycemia associated with other diabetes treatments. The sustained release formulation ensures a more uniform effect over the day, which can lead to better adherence to treatment and overall patient satisfaction.\n\nDosage and Administration\n\nDosage: The dosage should be individualized based on the patient’s current treatment regimen, effectiveness, and tolerability. It is crucial to monitor blood glucose levels regularly to ensure optimal control and to adjust the dosage as needed.\nAdministration: This medication should be taken with food, ideally with the first main meal of the day. The tablet must be swallowed whole to maintain the integrity of the sustained release mechanism and ensure effective drug delivery.\nSide Effects\nCommon side effects of GLICLAGALZE MR 60 may include gastrointestinal disturbances such as nausea and upset stomach. There is also a risk of hypoglycemia, particularly if meals are skipped or delayed, or when combined with other glucose-lowering medications.\n\nConclusion\nGLICLAGALZE MR 60 offers a reliable and effective approach for managing Type 2 diabetes, providing a balanced and prolonged action to stabilize blood glucose levels. It supports a comprehensive diabetes management plan, which should include regular physical activity, diet modification, and routine monitoring of blood glucose. As with any medication regimen, it is important to consult with a healthcare provider to adjust the treatment according to individual health needs and response to therapy.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/gliclagalze-mr-60-133418\n\n\n\n\n\n", "price": 128.0, "discountamount": 38.4, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "food", "peaks", "risks", "upset", "meals", "Order", "EMAIL", "member", "nausea", "tablet", "stomach", "therapy", "troughs", "reliable", "response", "balanced", "Benefits", "patients", "integrity", "adherence", "60 mg dose", "Conclusion", "key hormone", "bloodstream", "information", "tolerability", "Introduction", "fluctuations", "sterispharma", "hypoglycemia", "sterisonline", "steady level", "effectiveness", "Gliclazide SR", "CALL/WHATSAPP", "uniform effect", "GLICLAGALZE MR", "SR formulation", "gradual release", "optimal control", "Type 2 diabetes", "oral medication", "first main meal", "prolonged action", "diet modification", "moderate increase", "blood sugar levels", "sulfonylurea class", "consistent control", "effective approach", "insulin production", "routine monitoring", "medication regimen", "Common side effects", "healthcare provider", "blood glucose levels", "diabetes medications", "pancreatic beta cells", "Administration Dosage", "effective drug delivery", "individual health needs", "current treatment regimen", "other diabetes treatments", "regular physical activity", "overall diabetes management", "sustained release mechanism", "overall patient satisfaction", "sustained release formulation", "gastrointestinal disturbances", "other glucose-lowering medications", "comprehensive diabetes management plan" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1293, "imageuri": "https://productimages.withfloats.com/actual/665ef94b480b81124f8647ec.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/665ef94b480b81124f8647ec.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T11:23:52.299Z", "updatedon": "2024-06-04T11:23:52.299Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclagalze-mr-60-/1293", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGALZE MR 60 ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }